Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Arcellx Inc ( (ACLX) ).
On March 6, 2026, a purchaser launched a tender offer to acquire all outstanding shares of Arcellx Inc. common stock at $115 in cash plus a contingent value right (CVR) worth up to $5 per share, tied to cumulative worldwide sales of the company’s anito-cel product exceeding $6 billion by December 31, 2029. The offer expired on April 27, 2026, with about 77.2% of shares tendered, satisfying all conditions, and on April 28, 2026, the purchaser completed a merger under Delaware law, making Arcellx a wholly owned subsidiary and paying an aggregate of approximately $7.1 billion, including consideration for options and restricted stock units.
Following the merger’s effective time on April 28, 2026, all remaining eligible shares were converted into the same cash-and-CVR merger consideration, employee equity awards were cashed out or canceled as specified, and Arcellx moved to delist its shares from Nasdaq and terminate its SEC registration and reporting obligations. The transaction also triggered a full overhaul of corporate governance: all pre-merger directors and officers resigned, the acquirer’s leadership team assumed control, and the company’s certificate of incorporation and bylaws were amended and restated, underscoring Arcellx’s transition from a public to a privately held, parent-controlled entity.
The most recent analyst rating on (ACLX) stock is a Hold with a $115.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page.
Spark’s Take on ACLX Stock
According to Spark, TipRanks’ AI Analyst, ACLX is a Neutral.
Score is balanced between weak fundamentals (no 2025 revenue, widening losses, and worsening cash burn) and strong external/market support from the announced takeout plus very strong price momentum. Negative earnings (negative P/E) remains a valuation headwind, but the corporate event materially offsets financial risk in the near term.
To see Spark’s full report on ACLX stock, click here.
More about Arcellx Inc
Arcellx Inc. operates in the biopharmaceutical sector, focusing on the development and commercialization of innovative cell therapies. Its pipeline includes anitocabtagene autoleucel (anito-cel), a key product whose future worldwide sales are central to the contingent value rights structure in the company’s recent acquisition.
Average Trading Volume: 2,428,752
Technical Sentiment Signal: Buy
Current Market Cap: $6.73B
Learn more about ACLX stock on TipRanks’ Stock Analysis page.